vTv Therapeutics Inc. Class A Common Stock (VTVT)

Price$32.14

Value ScoreB

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)12.45%

Price vs S&P 500 (4W)4.77%

VGM Score51.20

Market Capitalization$129.75M

All Metrics

Book Value / Share (Quarterly)$22.84

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-36.70%

Cash Flow / Share (Quarterly)$-2.64

Price vs S&P 500 (YTD)-27.79%

Net Profit Margin (TTM)65.51%

EPS (TTM)$-0.92

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-0.92

Revenue Growth (5Y)-18.10%

EPS (Annual)$-3.20

ROI (Annual)-41.86%

Net Profit Margin (5Y Avg)-738.57%

Cash / Share (Quarterly)$24.90

P/E Basic Excl Extra (TTM)57.61x

ROA (Last FY)-30.00%

Revenue Growth TTM (YoY)216600.00%

EBITD / Share (TTM)$-0.29

Operating Margin (TTM)63.15%

Cash Flow / Share (Annual)$-6.41

P/B Ratio1.44x

P/B Ratio (Quarterly)1.74x

Net Income / Employee (Annual)$-1,037,500

EV / Revenue (TTM)0.86x

Net Interest Coverage (TTM)-1761.00x

ROA (TTM)2.86%

EPS Incl Extra (Annual)$-3.20

Current Ratio (Annual)13.54x

Quick Ratio (Quarterly)14.28x

3-Month Avg Trading Volume0.05M

52-Week Price Return-69.59%

P/E Incl Extra (TTM)57.61x

Revenue / Employee (TTM)$1,416,900

Tangible BV / Share (Quarterly)$-1.00

P/S Ratio (Annual)127.58x

Asset Turnover (Annual)0.03x

52-Week High$44.00

Operating Margin (5Y Avg)-995.06%

EPS Excl Extra (Annual)$-3.20

26-Week Price Return20.37%

Quick Ratio (Annual)13.42x

13-Week Price Return-13.65%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.36x

Enterprise Value$31.66M

Revenue / Share Growth (5Y)14.10%

Asset Turnover (TTM)0.37x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2222.71%

Cash / Share (Annual)$22.58

3-Month Return Std Dev81.22%

Net Income / Employee (TTM)$86,600

ROE (Last FY)-41.86%

Net Interest Coverage (Annual)-541.50x

EPS Basic Excl Extra (Annual)$-3.20

Receivables Turnover (TTM)12.40x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.92

Receivables Turnover (Annual)12.40x

ROI (TTM)3.95%

P/S Ratio (TTM)3.52x

Pretax Margin (5Y Avg)-976.86%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-0.43

Price vs S&P 500 (52W)-73.14%

P/E Ratio (TTM)57.61x

Year-to-Date Return-19.63%

5-Day Price Return-6.30%

EPS Normalized (Annual)$-3.20

ROA (5Y Avg)-74.14%

Net Profit Margin (Annual)-1815.34%

Month-to-Date Return-3.63%

Cash Flow / Share (TTM)$-13.50

EBITD / Share (Annual)$-3.89

Operating Margin (Annual)-2377.58%

P/E Excl Extra (TTM)57.61x

EPS Basic Excl Extra (TTM)$-0.92

P/B Ratio (Annual)2.59x

Pretax Margin (TTM)65.51%

Book Value / Share (Annual)$16.36

Price vs S&P 500 (13W)-21.90%

Beta0.30x

Revenue / Share (TTM)$2.52

ROE (TTM)3.96%

52-Week Low$14.00

vGradeB

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 261.94est. -0.10

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.18

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
VTVTvTv Therapeutics Inc. Class A Common Stock	B	C	D	$32.14
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small molecule drug candidates for diabetes and chronic diseases. The company's clinical pipeline is led by cadisegliatin, currently in Phase 3 trials, a potential first-in-class oral glucokinase activator for type 1 diabetes. vTv has a diverse pipeline of additional molecules in development across multiple disease indications.